PfizerImage may be NSFW.
Clik here to view.
(NYSE:PFE) and Flynn Pharma have appealed the record $107 million (£84.2 million) and $6.5 million (£5.2 million) fines imposed by the U.K. Competition & Markets Authority in December for the companies’ massive price hikes to their unbranded versions of anti-epilepsy drug Epanutin.
In its appeal, Pfizer claims that the regulator did not consider market realities when it fined the drugmaker, saying “Pfizer challenges the CMA’s conclusion that it was dominant within the relevant market: the market for the manufacture of Pfizer-manufactured phenytoin sodium capsules that are distributed in the UK.”
Get the full story at our sister site, Drug Delivery Business News.
The post Pfizer appeals $107m fine for anti-epilepsy drug prices in UK appeared first on MassDevice.
